drugset

drugset / Trial / NCT07680166

A Seamless, Adaptive Multiple-Ascending-Dose and Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

NCT07680166 ↗

Phase 1/2 Not yet recruiting 182 enrolled Xentria, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

A study of XTMAB-16 in patients with pulmonary sarcoidosis

Timeline

Start: 2026-10-30
Primary completion: 2029-10-31
Completion: 2029-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XTMAB-16	Unknown	4 mg/kg	Intravenous

Indications